Alzheimer's Disease

🔍 Five Things You Likely Didn’t Know About Alzheimer’s Disease

1. Alzheimer’s starts building in the brain 20 years before the first memory lapse. The molecular damage begins accumulating decades before any symptom appears. That enormous preclinical window is both sobering and hopeful: it means there is a long period during which targeted management of modifiable risk factors — cardiovascular health, cognitive engagement, sleep, hearing, and others — may genuinely slow or delay the onset of symptoms (Livingston et al., 2024).

2. Up to 40% of dementia risk is modifiable — including factors you might not expect. The Lancet Commission identified 14 modifiable risk factors — including hearing loss, social isolation, and air pollution — that collectively account for roughly 40% of dementia cases worldwide. That is a staggering figure for a disease most people assume is genetically predetermined.

3. The psychiatric symptoms are often harder on families than the memory loss itself. Agitation, paranoia, psychosis, and depression affect up to 90% of Alzheimer’s patients over the course of the illness. Families consistently describe these symptoms — not the cognitive decline — as the most difficult aspect of caregiving. And they are among the most treatable dimensions of the disease.

4. The amyloid hypothesis — the dominant theory for 30 years — is now being fundamentally revised. For decades, we operated on the assumption that amyloid plaques were the primary cause of Alzheimer’s and that clearing them would halt the disease. Billions of dollars and dozens of failed clinical trials later, a more nuanced picture is emerging: amyloid appears to be necessary but not sufficient (van Dyck et al., 2023). The field is now pivoting toward tau pathology, neuroinflammation, and metabolic dysfunction — a direction that may yield safer and more effective treatments over time.

5. A simple blood test can now detect Alzheimer’s pathology with over 90% accuracy. Blood-based biomarkers can now identify the protein changes characteristic of Alzheimer’s with diagnostic accuracy approaching 90% — rivaling invasive spinal fluid testing or expensive PET imaging (Ashton et al., 2024). In head-to-head comparisons, these blood tests outperformed clinical assessment by dementia specialists (roughly 90% vs. 73% accuracy). These tests signal a fundamental shift toward earlier, less invasive detection.

---

📋 Overview

Alzheimer’s disease is the most common cause of dementia, accounting for about three-quarters of all cases (Knopman et al., 2021). It is a progressive neurodegenerative disorder characterized by the gradual erosion of memory, thinking, reasoning, and the ability to perform everyday activities. The earliest and most prominent symptom is typically difficulty forming new memories — particularly episodic memories of recent events — though the disease eventually affects all cognitive domains, including language, visuospatial function, executive abilities, and social cognition.

The disease involves the progressive accumulation of abnormal proteins — amyloid plaques and tau tangles — along with inflammation, synaptic damage, and neuronal loss, particularly in brain regions critical for memory and attention.

Risk factors include advancing age (the single strongest predictor), genetic predisposition, cardiovascular disease, diabetes, traumatic brain injury, untreated depression and anxiety, and other modifiable lifestyle factors described above.

Cognitive reserve — built through education, intellectually demanding work, and social engagement — allows the brain to compensate for neurodegeneration up to a threshold. People with greater reserve tend to develop symptoms later, even when their brains show similar levels of damage.

---

🔀 Subtypes and Presentations

While the typical presentation of Alzheimer’s disease involves progressive memory impairment, several atypical variants deserve recognition:

• Typical (amnestic) Alzheimer’s — the most common presentation, beginning with impairment of episodic memory and gradually extending to other cognitive domains. This is the pattern most people associate with the disease.
• Posterior cortical atrophy (PCA) — sometimes called “visual Alzheimer’s,” this variant primarily affects visuospatial and visuoperceptual abilities. Patients may struggle with reading, judging distances, navigating familiar environments, or recognizing objects — while memory remains relatively preserved early on.
• Logopenic primary progressive aphasia — a language-dominant variant characterized by word-finding difficulty and impaired sentence repetition, often mistaken for a primary language disorder.
• Frontal variant Alzheimer’s — presents with prominent executive dysfunction, behavioral changes, and personality shifts, overlapping clinically with frontotemporal dementia.
• Early-onset Alzheimer’s — onset before age 65, accounting for approximately 5–10% of cases. This subgroup has a higher proportion of genetic (autosomal dominant) forms and often presents with atypical features. The psychosocial impact on patients still in their working and parenting years can be devastating.

These atypical presentations are frequently misdiagnosed or diagnosed late, underscoring the importance of comprehensive neuropsychiatric evaluation.

---

🩺 Diagnosis

Accurate diagnosis of Alzheimer’s disease requires a thorough, multimodal evaluation. Key elements include:

• Detailed clinical history — gathered from both the patient and a reliable informant (typically a family member or close friend). The pattern of cognitive decline, its timeline, its functional impact, and the presence of behavioral or psychiatric symptoms are all critical.
• Cognitive and neuropsychological testing — standardized instruments assess memory, language, executive function, attention, and visuospatial abilities. Brief screening tools can be useful but may miss early or atypical presentations; formal neuropsychological testing provides a more granular picture.
• Neuroimaging — structural MRI typically reveals hippocampal and temporoparietal atrophy. Amyloid PET imaging and cerebrospinal fluid biomarkers (amyloid-beta and phosphorylated tau) can confirm Alzheimer’s pathology in vivo, though their clinical utility and accessibility continue to evolve.
• Laboratory evaluation — blood work to rule out reversible causes of cognitive decline, including thyroid dysfunction, vitamin B12 deficiency, metabolic disturbances, and infectious etiologies. Emerging blood-based biomarkers for Alzheimer’s-specific pathology, as described above, are increasingly available and may complement this standard workup.
• Psychiatric assessment — depression, delirium, medication side effects, and sleep disorders can all mimic or exacerbate cognitive impairment and must be carefully evaluated. Late-life depression — including latent depression or unresolved trauma resurfacing due to recent cues or anniversaries — can present as “pseudodementia” — a cognitive syndrome that is typically reversible with treatment.

Early and accurate diagnosis allows for access to available treatments, advanced care planning, legal and financial preparation, and — perhaps most importantly — support and education for caregivers during a period when it can make the greatest difference.

---

💊 Treatment Approach

Alzheimer’s disease treatment is multifaceted and must address cognitive symptoms, behavioral and psychological symptoms, caregiver well-being, and overall quality of life. There is no cure, but there is far more that can be done than many families realize.

Psychotherapy and Behavioral Approaches

While traditional psychotherapy has a limited role in moderate-to-advanced Alzheimer’s, structured behavioral interventions and family psychoeducation are essential. Cognitive stimulation therapy has demonstrated modest but consistent benefits for cognition and quality of life in mild-to-moderate disease. Acceptance-based approaches — helping patients and families relate to cognitive losses with less distress and more psychological flexibility — can reduce the anxiety and grief that accompany the diagnosis. Behavioral management strategies, including structured routines, environmental modifications, and caregiver communication techniques, can meaningfully reduce agitation and aggression without medication.

Equally important is caregiver support. Alzheimer’s caregivers have markedly elevated rates of depression, anxiety, and burnout. Psychoeducation about disease progression, respite care planning, and referral to caregiver support groups or individual therapy are integral to comprehensive care — because the caregiver’s well-being directly shapes the patient’s quality of life.

Medication and Neuromodulation

The pharmacological treatment of Alzheimer’s involves two distinct domains: cognitive symptoms and neuropsychiatric symptoms.

For cognition, cholinesterase inhibitors remain a mainstay of treatment, working by boosting levels of acetylcholine — a neurotransmitter critical for memory and attention that is progressively depleted in Alzheimer’s. An NMDA receptor antagonist is often added in moderate-to-severe stages, modulating glutamatergic signaling to reduce excitotoxicity. These medications do not halt disease progression but can provide clinically meaningful stabilization, sometimes for months to years.

The newer anti-amyloid monoclonal antibodies represent a fundamentally different approach — targeting amyloid pathology directly rather than compensating for downstream neurotransmitter deficits. Their clinical benefit has been statistically significant, especially in the early stages of the disease, but they carry risks including cerebral edema and microhemorrhage that require careful monitoring. Whether these therapies represent a genuine turning point or an incremental step remains a subject of vigorous debate in the field.

For neuropsychiatric symptoms — the agitation, psychosis, depression, apathy, and sleep disruption that so profoundly affect patients and families — careful, judicious use of psychotropic medications can be genuinely transformative. The guiding principles are precision and restraint: targeting specific symptoms with the lowest effective doses, monitoring closely for adverse effects, and recognizing that this population is particularly vulnerable to medication-related complications. When done well, pharmacological management of behavioral symptoms is among the most impactful interventions available in Alzheimer’s care.

Integrative and Lifestyle Approaches

There is a growing body of evidence supporting multimodal lifestyle interventions for cognitive health — encompassing structured physical exercise, cardiovascular risk factor management, cognitive engagement, sleep optimization, and targeted nutritional strategies. The FINGER trial, a landmark Finnish randomized controlled trial, demonstrated that a comprehensive lifestyle intervention could improve or maintain cognitive function in at-risk older adults (Ngandu et al., 2015). Specific interventions targeting neuroinflammation, metabolic health, and the gut-brain axis are areas of active investigation that warrant individualized consideration. The details matter, and they are best discussed in the context of a thorough evaluation.

---

🌱 Outlook

Alzheimer’s disease is a progressive condition, and honesty about this trajectory is essential. The most important time to act is before symptoms emerge, by targeting modifiable risk factors. At the same time, the nihilism that has historically surrounded this diagnosis is not warranted. There is more that can be done today than at any previous point in history — both to slow cognitive decline and, equally importantly, to improve quality of life for patients and families throughout the course of the illness.

The behavioral and psychological symptoms of Alzheimer’s — which are often the primary source of distress — are treatable. Sleep, mood, agitation, and psychosis can all be managed with appropriate intervention. Building cognitive reserve, managing vascular risk factors, maintaining physical and social activity, and optimizing overall medical care can influence the trajectory in ways that compound over time.

The research landscape is also evolving rapidly. Beyond amyloid-targeting therapies, emerging approaches focused on tau pathology, neuroinflammation, synaptic repair, and metabolic interventions are reshaping the therapeutic horizon. For families navigating this diagnosis today, the most important step is to work with clinicians who bring both deep expertise and genuine compassion to the complexity of this disease.

---

🏥 How to Get Better

At our psychiatry practice, we have extensive experience in treating the psychiatric dimensions of Alzheimer’s disease — including depression, agitation, and psychosis — bringing specialized knowledge of the medication sensitivities involved. We bring a thoughtful, evidence-based approach to managing them with medications – when needed – and psychotherapy, supplements, neuromodulation such as photobiomodulation, and holistic practices when applicable and preferred by the patient and/or their families.

Ready to get started? Schedule an intake appointment — a thorough evaluation where we clarify your diagnosis, map out your treatment plan, and get everything moving: medication orders, therapy, supplements, and nutrition. Your care begins the same day, not weeks later.

Schedule Your Intake

We offer statewide telehealth services in California and Florida, with in-person appointments available in Los Angeles and Miami. We also regularly assist international patients due to our fluency in Portuguese, Spanish, and Farsi.

---

📚 References

1. Jack, C. R., Knopman, D. S., Jagust, W. J., et al. (2013). Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology, 12(2), 207–216.
2. Livingston, G., Huntley, J., Liu, K. Y., et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572–628.
3. Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., et al. (2011). Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimer’s & Dementia, 7(5), 532–539.
4. van Dyck, C. H., Swanson, C. J., Aisen, P., et al. (2023). Lecanemab in early Alzheimer’s disease. New England Journal of Medicine, 388(1), 9–21.
5. Ngandu, T., Lehtisalo, J., Solomon, A., et al. (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet, 385(9984), 2255–2263.
6. Knopman, D. S., Amieva, H., Petersen, R. C., et al. (2021). Alzheimer disease. Nature Reviews Disease Primers, 7(1), 33.
7. Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44(12), 2308–2314.
8. Stern, Y. (2012). Cognitive reserve in ageing and Alzheimer’s disease. The Lancet Neurology, 11(11), 1006–1012.
9. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Publishing.
10. Ballard, C., & Corbett, A. (2010). Management of neuropsychiatric symptoms in people with dementia. CNS Drugs, 24(9), 729–739.
11. Ashton, N. J., Brum, W. S., Di Molfetta, G., et al. (2024). Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurology, 81(3), 255–263.